This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sept 2026 quarter: revenue up 24%, profit after tax down 11% year on year
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Smallcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Sept 2026 quarter: revenue up 24% to Rs 969 crore and profit after tax down 11% to Rs 73 crore, both year on year. Operating profit before finance cost, tax, depreciation and other income fell from 22.8% to 17.9% of revenue. Board approved the results. Consolidated six months: profit after tax Rs 180 crore versus a Rs 26 crore loss; operating cash flow Rs 237 crore. Related-party loans: Rs 80 crore received, Rs 156 crore repaid.
Revenue growth helps, but lower quarterly profit and margin compression weigh on the stock; half-year profit turnaround and positive cash flow help.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹969.0 Cr | ₹782.0 Cr | +23.9% |
| Operating profit | ₹62.00 Cr | ₹70.00 Cr | −11.4% |
| Profit after tax | ₹73.00 Cr | ₹82.00 Cr | −11.0% |
| EBITDA margin | 17.9% | 22.8% | −4.9 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.